Peptide Therapeutics
•15 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (15)
%
| Company | Market Cap | Price |
|---|---|---|
|
Peptide therapeutics reflect Merck's exploration of next-gen peptide-based approaches (e.g., oral GLP-1 programs).
|
$200.78B |
$79.96
-0.16%
|
|
Dr. Reddy's is targeting GLP-1 peptide therapeutics (semaglutide) with a vertically integrated peptide API/manufacturing platform.
|
$11.96B |
$14.34
+1.63%
|
|
Metsera's core focus is developing peptide-based obesity/metabolic therapies delivered via injectable and oral routes, under proprietary platforms (MINT, HALO, MOMENTUM), qualifying as a peptide therapeutics investable theme.
|
$5.55B |
$52.87
+0.84%
|
|
VK2735 is a peptide-based therapeutic (dual GLP-1/GIP receptor agonist), placing it squarely in the Peptide Therapeutics category.
|
$3.77B |
$33.56
-6.13%
|
|
MBX directly develops peptide-based therapeutics under its Precision Endocrine Peptide platform, fitting the Peptide Therapeutics category.
|
$557.85M |
$16.69
-0.36%
|
|
Peptide-based targeting constructs used in radiopharmaceuticals (e.g., peptide-targeted radiopharmaceuticals).
|
$360.75M |
$4.86
+15.71%
|
|
TX45 is a peptide-based therapeutic protein (Fc-relaxin fusion) targeting GPCR RXFP1.
|
$299.13M |
$16.02
-6.10%
|
|
Nomlabofusp is a peptide-based therapeutic delivered as a recombinant fusion protein, aligning with Peptide Therapeutics.
|
$279.16M |
$4.36
-3.75%
|
|
LINZESS (linaclotide) and apraglutide are peptide-based therapeutics, placing Ironwood in the Peptide Therapeutics category.
|
$256.48M |
$1.58
-15.24%
|
|
EB613 and other pipeline candidates are peptide therapeutics administered orally, fitting the Peptide Therapeutics category.
|
$120.45M |
$2.65
+6.00%
|
|
Certepetide is a peptide therapeutic, placing Lisata in the Peptide Therapeutics category.
|
$20.38M |
$2.37
|
|
The company is developing a ~60-day GLP-1 receptor agonist peptide, placing it in the Peptide Therapeutics category.
|
$15.11M |
$3.15
-3.96%
|
|
hCDR1 is a peptide-based therapeutic, placing the company under Peptide Therapeutics.
|
$7.63M |
$1.40
-11.39%
|
|
Core asset class is peptide therapeutics, aligning with Peptide Therapeutics.
|
$5.65M |
$0.04
|
|
SPU-16 program involves a CNS-homing peptide, aligning with Peptide Therapeutics.
|
$2.52M |
$0.56
-16.31%
|
Loading industry metrics...
Loading comparison data...
